Logo

AstraZeneca Report Results of Farxiga in P-III DAPA-CKD Study for Patients with Chronic Kidney Disease

Share this

AstraZeneca Report Results of Farxiga in P-III DAPA-CKD Study for Patients with Chronic Kidney Disease

Shots:

  • The P-III DAPA-CKD involve assessing of Farxiga ((dapagliflozin- 10mg- qd) + SOC vs PBO in 4-304 patients with CKD Stages 2–4 and elevated urinary albumin excretion- with and without T2D
  • The study met its 1EPs i.e. worsening of renal function or risk of death (defined as a composite of an eGFR decline ≥50%- the onset of ESKD and death from CV/ renal cause) and 2EPs i.e. time to first occurrence of the renal composite (sustained ≥50% eGFR decline- ESKD- and renal death
  • Farxiga (PO- qd) is an SGLT2 inhibitor indicated in adults for the treatment of insufficiently controlled T2D as both monothx. and combination therapy as an adjunct to diet and exercise to improve glycemic control- weight loss and BP reduction

­ Ref: AstraZeneca | Image: Bloomberg Quint

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions